TIAF1 Antibody

What is TIAF1 and why is it important for research?

TIAF1 (TGFB1-Induced Anti-Apoptotic Factor 1) is a small protein of approximately 12-16.6 kDa that functions as a cytotoxic granule-associated RNA-binding protein. It plays critical roles in inhibiting the cytotoxic effects of TNF-alpha and overexpressed TNF receptor adapters TRADD, FADD, and RIPK1 . This protein is involved in TGF-beta1 inhibition of IkappaB-alpha expression and suppression of TNF-mediated IkappaB-alpha degradation. Importantly, TIAF1 significantly impacts cellular stress responses by regulating mRNA translation and splicing as well as promoting stress granule formation .

Research interest in TIAF1 has increased substantially due to its implications in various pathological conditions. TIAF1 self-aggregation has been linked to the generation of Aβ and amyloid fibrils from amyloid precursor protein (APP), suggesting its potential role in neurodegenerative disorders . Studies have also demonstrated that TIAF1 is essential in p53- and WOX1-mediated cell death pathways and exhibits aggregation-dependent control of tumor progression, metastasis, and cell death regulation .

How do I select the appropriate TIAF1 antibody for my experiments?

Selecting the optimal TIAF1 antibody requires careful consideration of several experimental parameters:

• Experimental application: First determine whether your application is Western blot, immunohistochemistry, immunofluorescence, ELISA, or immunoprecipitation, as different antibodies have varying performance across applications .

• Species reactivity: Verify that the antibody recognizes TIAF1 in your species of interest. Available antibodies react with human, mouse, or both depending on the product .

• Antibody format: Consider whether monoclonal or polyclonal antibodies better suit your research needs:

  • Monoclonal antibodies (e.g., Mouse Monoclonal 3B9) offer high specificity to a single epitope

  • Polyclonal antibodies recognize multiple epitopes, potentially providing stronger signals but with possible increased background

• Validation data: Review characterization data provided by manufacturers, including knockout cell line validation, which represents the gold standard for antibody specificity confirmation .

For high-confidence results, consider antibodies that have been validated through standardized protocols using knockout cell lines and isogenic parental controls, particularly if studying endogenous protein localization or protein-protein interactions .

What are the critical storage and handling considerations for TIAF1 antibodies?

Proper storage and handling of TIAF1 antibodies are crucial for maintaining their performance and extending their shelf life:

• Storage temperature: Most TIAF1 antibodies should be stored at -20°C for long-term storage . Some products may recommend 4°C for shorter periods after reconstitution.

• Buffer composition: Be aware of the storage buffer constituents, as they may affect experimental outcomes. Common formulations include:

  • PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

  • 20 mM Tris-HCl buffer (pH 8.0) containing additives like urea and glycerol for recombinant proteins

• Freeze-thaw cycles: Minimize repeated freezing and thawing, which can degrade antibody quality. Consider aliquoting antibodies upon receipt to reduce the number of freeze-thaw cycles .

• Shelf life: Most antibodies are stable for approximately one year after shipment when stored properly .

• Working concentrations: Dilute antibodies fresh before use to the manufacturer-recommended working concentration, which varies by application:

  • Western Blot: 1:500-1:3000

  • Immunohistochemistry: 1:20-1:200

  • Immunofluorescence: 1:20-1:200

It is always advisable to perform titration experiments to determine the optimal antibody concentration for your specific experimental system.

How can I validate TIAF1 antibody specificity for my research application?

Validating antibody specificity is critical for generating reliable data. For TIAF1 antibodies, consider implementing the following comprehensive validation strategy:

• Knockout cell validation: The gold standard approach is comparing signals between wild-type cells and TIAF1 knockout cells generated using CRISPR/Cas9 technology. This approach definitively confirms antibody specificity by demonstrating absence of signal in knockout samples .

• Multiple antibody validation: Employ at least two independent antibodies targeting different epitopes of TIAF1. Concordant results between different antibodies increase confidence in specificity .

• Recombinant protein controls: Use purified recombinant TIAF1 protein (such as ABIN1098676) as a positive control in Western blot applications. This protein can be used for antibody pre-absorption tests to confirm specificity .

• siRNA knockdown: Transiently reduce TIAF1 expression using siRNA and confirm corresponding reduction in antibody signal. This approach is particularly valuable when knockout cells are unavailable .

• Cross-reactivity assessment: Test antibody against related proteins, particularly MYO18A, which is sometimes confused with TIAF1 in databases and literature .

For immunofluorescence applications, perform co-localization studies with markers of known TIAF1-associated compartments, as TIAF1 has been shown to localize to the nucleus and associate with stress granules .

What are the optimal protocols for detecting TIAF1 self-aggregation in neurodegenerative disease models?

Detecting TIAF1 self-aggregation requires specialized approaches due to its relevance in neurodegenerative pathologies:

• Filter retardation assay:

  • Prepare cell or tissue lysates in 1% SDS buffer

  • Filter through a cellulose acetate membrane (0.2 μm pore size)

  • Only aggregated proteins are retained on the membrane

  • Probe with anti-TIAF1 antibodies

  • This method has successfully detected TIAF1 aggregates in hippocampi of non-demented humans and AD patients

• Sequential extraction protocol:

  • First extract soluble proteins with RIPA buffer

  • Re-extract the remaining pellet with urea-containing buffer to solubilize aggregated proteins

  • Compare TIAF1 distribution between fractions using Western blot

  • Higher levels in the urea-soluble fraction indicate aggregation

• Co-immunoprecipitation of TIAF1 with amyloid proteins:

  • Immunoprecipitate with anti-TIAF1 antibodies

  • Probe Western blots for APP, Aβ, or other amyloid markers

  • This approach has demonstrated that polymerized TIAF1 physically interacts with amyloid fibrils

• Immunohistochemistry with formic acid pretreatment:

  • Pretreat tissue sections with 70% formic acid for 5-10 minutes

  • This step enhances epitope exposure in protein aggregates

  • Subsequently perform standard IHC protocol with anti-TIAF1 antibodies

  • Compare patterns with amyloid-specific stains on consecutive sections

For quantitative assessment of temporal relationships between TIAF1 aggregation and Aβ formation, combined approaches using both TIAF1 and Aβ antibodies on the same samples provide valuable insights into disease progression mechanisms .

How can I optimize Western blot protocols specifically for TIAF1 detection?

Optimizing Western blot protocols for TIAF1 detection requires careful attention to several specific parameters:

• Sample preparation:

  • Include protease inhibitors in lysis buffer to prevent degradation

  • For detecting TIAF1 in its monomeric form (~12-16.6 kDa), use reducing conditions

  • For studying aggregation, consider non-reducing conditions or native PAGE

  • Sonicate samples briefly to break down DNA and reduce viscosity

• Gel selection and transfer parameters:

  • Use 15-18% polyacrylamide gels or gradient gels (4-20%) to effectively resolve low molecular weight proteins

  • Transfer to PVDF membrane at lower voltage (30V) overnight at 4°C for better retention of small proteins

  • Consider semi-dry transfer protocols which can be more efficient for small proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST

  • Primary antibody dilutions typically range from 1:500 to 1:3000

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

  • Secondary antibody dilutions typically 1:5000 to 1:10000

  • Consider using TBS instead of PBS if high background is observed

• Detection and visualization:

  • Enhanced chemiluminescence (ECL) is sufficient for standard detection

  • For low abundance samples, consider using high-sensitivity ECL substrates

  • Exposure times may need to be longer than standard (1-5 minutes) for detecting endogenous TIAF1

• Controls to include:

  • Positive control: PC-3 cells which are known to express TIAF1

  • Recombinant TIAF1 protein as a migration reference

  • TIAF1-knockout cell lysate as negative control if available

For detecting specific isoforms or modified forms of TIAF1, Western blot conditions may need further optimization based on the specific research question.

How do I distinguish between TIA1 and TIAF1 in experimental systems?

Distinguishing between TIA1 (T-cell intracellular antigen-1) and TIAF1 (TGFB1-induced anti-apoptotic factor 1) is crucial as these proteins are often confused in the literature but have distinct functions:

• Antibody selection for specificity:

  • Verify the exact target by checking the antibody datasheet for the immunogen sequence

  • For TIAF1, look for antibodies recognizing epitopes from UniProt ID O95411

  • For TIA1, select antibodies against UniProt ID P31483

  • Examine cross-reactivity data in the antibody documentation

• Molecular weight differentiation:

  • TIAF1 migrates at approximately 12 kDa on SDS-PAGE

  • TIA1 typically appears as two splice variants at approximately 40 kDa (TIA1a) and 42 kDa (TIA1b)

  • Use this size difference to confirm target identity on Western blots

• Functional validation experiments:

  • TIAF1 interacts with TGF-β signaling pathways and inhibits TNF-mediated effects

  • TIA1 functions primarily in RNA metabolism and stress granule formation

  • Design functional assays targeting these distinct pathways

• Subcellular localization patterns:

  • TIAF1 localizes primarily to the nucleus under normal conditions

  • TIA1 shuttles between nucleus and cytoplasm, forming characteristic cytoplasmic puncta (stress granules) under stress conditions

  • Use immunofluorescence with specific antibodies to distinguish localization patterns

• Genetic manipulation:

  • Use gene-specific siRNAs or CRISPR-Cas9 targeting unique sequences

  • Confirm knockdown/knockout with gene-specific qPCR primers

  • Validate protein reduction with specific antibodies

The confusion between these proteins in the literature necessitates careful validation throughout experimental design and data interpretation.

What methodologies should I use to study TIAF1's role in regulating cell death and apoptosis?

To elucidate TIAF1's role in cell death and apoptosis regulation, implement a multi-faceted experimental approach:

• Genetic manipulation of TIAF1 expression:

  • Knockdown: Use siRNA or shRNA targeting TIAF1 (suppress UV irradiation-mediated p53 phosphorylation)

  • Overexpression: Transfect cells with TIAF1 expression constructs (potentially increases resistance to TNF-induced apoptosis)

  • CRISPR-Cas9: Generate TIAF1 knockout cell lines for complete loss-of-function studies

• Cell death assays following TIAF1 modulation:

  • Annexin V/PI staining with flow cytometry to quantify apoptotic cells

  • TUNEL assay to detect DNA fragmentation

  • Caspase activation assays (especially caspase 3/7) to measure apoptotic signaling

  • MTT or SRH assays to assess cell viability

  • Compare responses to various death stimuli (TNF-α, FasL, staurosporine, etc.)

• Molecular pathway analysis:

  • Western blot analysis of key signaling proteins:

    • NF-κB pathway: Monitor IκB-α degradation and p65 phosphorylation

    • p53 pathway: Assess phosphorylation status and nuclear translocation

    • Pro-survival pathways: Evaluate Bcl-2, Bcl-xL, and Mcl-1 levels

    • Pro-apoptotic markers: Measure Bax, Bak, and cytochrome c release

  • Co-immunoprecipitation to identify TIAF1 interaction partners during apoptosis

• Advanced microscopy techniques:

  • Live-cell imaging with fluorescently tagged TIAF1 to track dynamics during apoptosis

  • FRET or BiFC assays to study protein-protein interactions in real-time

  • Super-resolution microscopy to visualize TIAF1 aggregation state changes

• In vivo validation studies:

  • Generate tissue-specific TIAF1 knockout mouse models

  • Analyze tissue homeostasis and response to apoptotic stimuli

  • Correlate findings with human tissue samples from relevant disease states

This multi-level approach can provide comprehensive insights into how TIAF1 regulates the balance between cell survival and death in both physiological and pathological contexts.

How can I investigate the relationship between TIAF1 aggregation and amyloid pathology in neurodegenerative diseases?

Investigating the relationship between TIAF1 aggregation and amyloid pathology requires specialized approaches spanning molecular, cellular, and tissue levels:

• Tissue-level analysis of human samples:

  • Perform sequential immunohistochemistry on brain sections from AD patients and controls:

    • First stain for TIAF1 aggregates

    • Document precise locations of TIAF1-positive aggregates

    • Re-stain the same section for Aβ plaques

    • Quantify co-localization and temporal-spatial relationships

  • Implement filter retardation assays on human brain homogenates to quantitatively assess TIAF1 and Aβ aggregation levels in different brain regions and disease stages

• Cellular models of aggregation:

  • Establish cell lines expressing fluorescently-tagged TIAF1 and APP

  • Apply TGF-β stimulation and environmental stressors to induce TIAF1 aggregation

  • Track the temporal sequence of:

    • TIAF1 self-aggregation

    • APP dephosphorylation at Thr668

    • APP degradation

    • Generation of AICD and Aβ

  • Use high-content imaging to quantify the progression of these events

• Biochemical interaction studies:

  • Perform in vitro aggregation assays with purified recombinant TIAF1 protein

  • Assess direct interaction between polymerized TIAF1 and synthetic amyloid fibrils

  • Use surface plasmon resonance or microscale thermophoresis to determine binding affinities

  • Investigate whether TIAF1 accelerates or inhibits Aβ fibril formation using thioflavin T assays

• Transgenic animal models:

  • Create double transgenic mice overexpressing both TIAF1 and mutant APP

  • Compare with single transgenic controls (TIAF1-only and APP-only)

  • Analyze:

    • Age-dependent TIAF1 aggregation

    • Amyloid plaque formation

    • Cognitive deficits

    • Neurodegeneration patterns

• Therapeutic intervention studies:

  • Test compounds that specifically disrupt TIAF1 aggregation

  • Assess downstream effects on amyloid pathology

  • Evaluate potential for disease-modifying effects in cellular and animal models

This comprehensive approach can establish whether TIAF1 aggregation represents an upstream event in AD pathogenesis and potentially identify new therapeutic targets for intervention.

How do I troubleshoot low or variable TIAF1 signal in Western blot experiments?

When encountering low or inconsistent TIAF1 signals in Western blotting, consider the following systematic troubleshooting approach:

• Sample preparation optimization:

  • Ensure complete cell lysis using stronger lysis buffers (RIPA with 0.1% SDS)

  • Add fresh protease inhibitors to prevent degradation of the small TIAF1 protein

  • For tissues, consider specialized extraction protocols optimized for small proteins

  • Include phosphatase inhibitors if studying phosphorylated forms of TIAF1

  • Quantify protein concentration carefully and load adequate amounts (30-50 μg total protein)

• Gel electrophoresis and transfer adjustments:

  • Use higher percentage gels (15-18%) to better resolve the small TIAF1 protein

  • Consider using Tricine-SDS-PAGE instead of Tris-glycine for better resolution of small proteins

  • Optimize transfer conditions:

    • Wet transfer with 10-20% methanol buffer

    • Lower voltage (30V) overnight at 4°C

    • Use 0.2 μm PVDF membrane instead of 0.45 μm for better retention

• Antibody selection and optimization:

  • Try alternative TIAF1 antibodies that recognize different epitopes

  • Test a range of primary antibody concentrations (1:250 to 1:3000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use more sensitive detection methods (high-sensitivity ECL substrates)

• Positive controls and reference samples:

  • Include PC-3 cells as positive control, which consistently show TIAF1 expression

  • Use recombinant TIAF1 protein as reference standard

  • Consider overexpression of TIAF1 in your cell line as a positive control

• Addressing specificity concerns:

  • Pre-absorb antibody with recombinant TIAF1 to confirm specificity

  • If possible, include TIAF1 knockout samples as negative controls

  • Verify molecular weight matches expected size for TIAF1 (approximately 12 kDa)

For particularly challenging samples, consider enrichment approaches such as immunoprecipitation of TIAF1 before Western blotting to increase sensitivity.

What factors should I consider when optimizing immunofluorescence protocols for TIAF1 detection?

Optimizing immunofluorescence protocols for TIAF1 requires attention to several critical factors:

• Fixation method selection:

  • Test multiple fixation approaches:

    • 4% paraformaldehyde (10-15 minutes) preserves morphology but may mask some epitopes

    • Methanol fixation (-20°C, 10 minutes) can improve accessibility to some nuclear epitopes

    • Combined fixation (brief PFA followed by methanol) can be optimal for certain epitopes

  • Always perform fixation optimization with your specific TIAF1 antibody

• Antigen retrieval techniques:

  • For formalin-fixed tissues or challenging cell samples:

    • Try heat-mediated antigen retrieval with citrate buffer (pH 6.0)

    • Alternatively, use TE buffer (pH 9.0) as recommended for some TIAF1 antibodies

    • Test enzymatic retrieval with proteinase K for certain applications

• Permeabilization optimization:

  • TIAF1 has nuclear localization in many contexts, requiring effective nuclear permeabilization

  • Test different detergents and concentrations:

    • 0.1-0.5% Triton X-100 (5-15 minutes)

    • 0.1-0.2% Saponin (10 minutes)

    • 0.1% SDS (1-2 minutes) for resistant samples

• Blocking and antibody incubation parameters:

  • Use 5-10% normal serum from the species of the secondary antibody

  • Add 0.1-0.3% Triton X-100 to blocking buffer for continued permeabilization

  • Extend primary antibody incubation (overnight at 4°C)

  • Test antibody dilutions in the range of 1:20-1:200 as recommended

• Signal amplification strategies:

  • For low abundance TIAF1 detection:

    • Consider tyramide signal amplification (TSA)

    • Use high-sensitivity detection systems

    • Optimize microscope settings (longer exposure, higher gain)

  • Balance signal amplification with background control

• Confirming specificity with controls:

  • Include peptide competition controls to verify antibody specificity

  • Use TIAF1 knockdown or knockout cells as negative controls

  • Co-stain with markers of expected subcellular localization

Document all optimization steps systematically and maintain consistent protocols once optimized for reproducible results.

How can I address cross-reactivity concerns when studying TIAF1 in complex biological samples?

Addressing cross-reactivity concerns is critical for generating reliable data with TIAF1 antibodies, particularly given the potential confusion with other proteins:

• Comprehensive antibody validation:

  • Validate each antibody lot with:

    • Western blot of recombinant TIAF1 protein

    • TIAF1 overexpression lysates

    • TIAF1 knockout/knockdown samples

  • Perform peptide competition assays to confirm epitope specificity

  • Test on multiple cell lines with known TIAF1 expression profiles

• Addressing MYO18A confusion:

  • TIAF1 is sometimes incorrectly associated with MYO18A in databases

  • Confirm your antibody specifically recognizes TIAF1 (12 kDa) and not MYO18A (≈233 kDa)

  • Use molecular weight as a distinguishing factor in Western blots

  • When studying TIAF1 in complex samples, verify results with two independent antibodies targeting different epitopes

• Species cross-reactivity considerations:

  • Verify your antibody's species reactivity claims:

    • Some antibodies are human-specific (ABIN1327101, ABIN6388520)

    • Others recognize both human and mouse TIAF1 (ABIN6265565)

    • Some antibodies claim reactivity to human, mouse, and rat (A02344-1)

  • Validate species reactivity experimentally before cross-species comparisons

• Immunodepletion approach:

  • For complex tissue samples, consider sequential immunodepletion:

    • First deplete samples with antibodies against potential cross-reactive proteins

    • Then analyze the depleted sample for TIAF1

  • Compare results before and after depletion to identify potential cross-reactivity

• Mass spectrometry validation:

  • For definitive identification in complex samples:

    • Perform immunoprecipitation with anti-TIAF1 antibody

    • Analyze the precipitated proteins by mass spectrometry

    • Verify the presence of TIAF1-specific peptides

    • Identify any co-precipitating proteins that might be confused with TIAF1

• Epitope mapping:

  • For antibodies where the epitope is not disclosed:

    • Use epitope mapping techniques to identify the recognized region

    • Compare with sequence alignments to identify potential cross-reactive proteins

    • Select antibodies targeting unique TIAF1 epitopes

These approaches collectively minimize the risk of misinterpreting data due to antibody cross-reactivity issues.

How can I apply newer antibody technologies to study endogenous TIAF1 in live cells?

Newer antibody technologies enable more sophisticated studies of endogenous TIAF1 in living cellular systems:

• Intrabody approaches:

  • Engineer anti-TIAF1 single-chain variable fragments (scFvs) from existing antibodies

  • Express these intrabodies fused to fluorescent proteins

  • This approach allows visualization of endogenous TIAF1 without overexpression artifacts

  • Optimize with appropriate subcellular localization signals if needed

  • Validate specificity using TIAF1 knockout controls

• Nanobody technology:

  • Develop anti-TIAF1 nanobodies (single-domain antibodies derived from camelids)

  • Advantages include:

    • Small size (~15 kDa) for better penetration

    • Stability in reducing intracellular environments

    • High specificity and affinity

  • Express as GFP-fusion proteins for live imaging

  • Can be used for acute protein degradation approaches when fused to degron domains

• Split-fluorescent protein complementation:

  • Tag TIAF1 with one half of a split fluorescent protein using CRISPR knock-in

  • Express the complementary half fused to an anti-TIAF1 nanobody

  • Binding results in fluorescence only when TIAF1 is present

  • Allows quantitative assessment of endogenous TIAF1 levels

• Antibody-based FRET sensors:

  • Design FRET sensors using two antibody fragments recognizing different TIAF1 epitopes

  • Enables detection of conformational changes or aggregation states

  • Particularly valuable for studying TIAF1 aggregation dynamics in neurodegeneration models

• Proximity labeling approaches:

  • Express engineered peroxidases (APEX) or biotin ligases (TurboID) fused to anti-TIAF1 antibody fragments

  • Upon binding to endogenous TIAF1, these enzymes label proximal proteins

  • Enables mapping of the dynamic TIAF1 interactome under various conditions

  • Particularly useful for identifying partners during stress granule formation or aggregation

These advanced approaches enable dynamic studies of endogenous TIAF1 without the artifacts associated with overexpression systems, providing more physiologically relevant insights.

What are the most effective approaches to study TIAF1's role in RNA metabolism and stress granule formation?

Investigating TIAF1's functions in RNA metabolism and stress granule dynamics requires specialized methodologies:

• RNA-protein interaction analysis:

  • RNA immunoprecipitation (RIP) using validated TIAF1 antibodies

  • CLIP-seq (Cross-linking immunoprecipitation) to identify direct RNA targets

  • RNA electrophoretic mobility shift assays (EMSA) with recombinant TIAF1

  • Functional studies comparing wild-type and mutant TIAF1 RNA-binding domains

  • Analyze binding preference for 3' uridine-rich RNA sequences

• Stress granule dynamics visualization:

  • Live-cell imaging with fluorescently tagged TIAF1

  • Co-staining with established stress granule markers (G3BP1, TIA1, PABP)

  • Quantify:

    • Kinetics of TIAF1 recruitment to stress granules

    • Co-localization coefficients with other RNA-binding proteins

    • Granule size, number, and disassembly rates

  • Compare across different stressors (arsenite, heat shock, oxidative stress)

• Genetic manipulation approaches:

  • CRISPR-Cas9 knockout of TIAF1

  • Domain-specific mutations of RNA-binding regions

  • Rescue experiments with wild-type vs. mutant TIAF1

  • Assess impact on:

    • Global translation rates (puromycin incorporation)

    • Stress granule formation and dissolution

    • Cell survival under stress conditions

• Integrated omics approaches:

  • RNA-seq following TIAF1 modulation to identify regulated transcripts

  • Ribosome profiling to assess translation efficiency changes

  • Parallel RNA-seq and proteomics to distinguish transcriptional vs. translational regulation

  • Bioinformatic analysis for enriched sequence motifs and biological pathways

• Advanced microscopy techniques:

  • Super-resolution microscopy to visualize TIAF1 within stress granule substructures

  • FRAP (Fluorescence Recovery After Photobleaching) to measure TIAF1 dynamics

  • Optogenetic approaches to trigger localized TIAF1 aggregation

  • Correlative light and electron microscopy to examine ultrastructural features of TIAF1-containing granules

These approaches collectively provide a comprehensive understanding of TIAF1's dual roles in RNA metabolism and stress response regulation, potentially revealing therapeutic targets for diseases associated with dysregulated RNA metabolism.